VEEVVeeva Systems
Is the price fair?
Neither cheap nor expensive: nothing decisive, though cheap against its own history.
Cheap vs its own history: P/E 48.5 vs a 71.4 median over 41 quarters (−32% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What VEEV's price assumes
Veeva Systems trades at 48.5× earnings against 46.0× for the median Health Information Services name, more expensive than its own group.
Trailing P/E · Health Information Services median 46.0 · 1.05× the median: the market pays up for this one
- Price / sales
- 7.79
Price / sales · today's price, fiscal year to Jan 31, 2026
- Price / book
- 3.45
Price / book · today's price, fiscal year to Jan 31, 2026
- EV / sales
- 5.74
EV / sales
Details›
- Price / booktoday's price, fiscal year to Jan 31, 2026
- 3.45
- EV / EBITtoday's price, fiscal year to Jan 31, 2026
- 20.0
- EV / salestoday's price, fiscal year to Jan 31, 2026
- 5.74
- Healthcare median P/E509 names
- 26.2
- Health Information Services median P/E25 names
- 46.0
- Market capitalisation
- $24.9B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $346.83 |
| Its own P/E history, median | $436.05 |
| Its own P/E history, upper quartile | $549.53 |
| 52-week range | $151.43 – $306.22 |
| Today | $296.04 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
The closest names by size in the same industry